Cancer treatments are increasingly successful in managing the disease on a long-term basis. However, funding these drugs is becoming ever more expensive, writes Dr Gary Bolger
There is a sea change underway in the treatment of cancer, and the key to this has been the arrival of new types of drugs - drugs that work in different ways from traditional cancer chemotherapy. These new treatments use our increasing knowledge of the molecular biology of how cells work and how they communicate with one another. Some of these drugs, such as the monoclonal antibodies Avastin and Herceptin, are already here and licensed for use in specific circumstances. Many others are in the pipeline and are expected to enter the market over the next few years. An important feature of...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes





